Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alexza Finds New U.S. Marketing Partner For Adasuve In Teva

This article was originally published in The Pink Sheet Daily

Executive Summary

A quick-acting, inhaled antipsychotic, Adasuve has been approved in the U.S. and EU, where it will be commercialized by Spain’s Grupo Ferrer. Teva takes over after previous U.S. partner Biovail stepped away upon being bought out by Valeant.

You may also be interested in...



Alexza's Last Stand: Hoping For Buyout Or License Of Adasuve

Facing a potential shutdown at the end of April, the California drug-delivery firm hopes either to be purchased by its Spanish partner or find a new licensee of US rights to its inhalable antipsychotic.

EU's CHMP Clears Selincro And Perjeta, Rejects Kynamro And Fanaptum

Europe's top scientific advisory panel backed Lundbeck's alcoholism therapy Selincro (nalmefene) and Roche's next-generation breast cancer therapy Perjeta (pertuzumab) but rejected Genzyme/Isis' antisense therapy Kynamro (mipomersen) and Vanda's Fanaptum (oral iloperidone).

Alexza Expects FDA, EU Regulatory Decisions On Adusave This December

Firm has responded to a second “complete response” letter from FDA and to questions from EU regulators regarding its proposed inhalation formulation of antipsychotic loxapine.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel